Pedrolli Danielle Biscaro, Jankowitsch Frank, Schwarz Julia, Langer Simone, Nakanishi Shinobu, Mack Matthias
Institute for Technical Microbiology, Mannheim University of Applied Sciences, Paul-Wittsack-Str. 10, 68163, Mannheim, Germany.
Methods Mol Biol. 2014;1146:41-63. doi: 10.1007/978-1-4939-0452-5_3.
Riboflavin analogs have a good potential to serve as basic structures for the development of novel anti-infectives. Riboflavin analogs have multiple cellular targets, since riboflavin (as a precursor to flavin cofactors) is active at more than one site in the cell. As a result, the frequency of developing resistance to antimicrobials based on riboflavin analogs is expected to be significantly lower. The only known natural riboflavin analog with antibiotic function is roseoflavin from the bacterium Streptomyces davawensis. This antibiotic negatively affects flavoenzymes and FMN riboswitches. Another roseoflavin producer, Streptomyces cinnabarinus, was recently identified. Possibly, flavin analogs with antibiotic activity are more widespread than anticipated. The same could be true for flavin analogs yet to be discovered, which could constitute tools for cellular chemistry, thus allowing a further extension of the catalytic spectrum of flavoenzymes.
核黄素类似物具有作为新型抗感染药物开发基础结构的良好潜力。核黄素类似物有多个细胞靶点,因为核黄素(作为黄素辅因子的前体)在细胞中的多个位点都有活性。因此,基于核黄素类似物的抗菌药物产生耐药性的频率预计会显著更低。唯一已知具有抗生素功能的天然核黄素类似物是来自达瓦链霉菌的玫红菌素。这种抗生素会对黄素酶和FMN核糖开关产生负面影响。最近还鉴定出了另一种玫红菌素产生菌,即朱红链霉菌。可能具有抗生素活性的黄素类似物比预期的更为广泛。对于尚未发现的黄素类似物来说可能也是如此,它们可能构成细胞化学的工具,从而使黄素酶的催化谱得到进一步扩展。